[1]
W. Gulliver, “Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study”, J of Skin, vol. 2, no. S1, p. S52, Feb. 2018.